Список литературы к Главе 8

1. Габеева Н.Г. Современные принципы лечения различных форм хронического лимфолейкоза : автореф. дис. … канд. мед. наук. Москва, 2001.

2. Богданов А.Н. и др. ZAP­70 – маркер В­клеточного хронического лимфолейкоза // Вопросы онкологии. 2008. Т. 54, № 1. С. 7–18.

3. Кисиличина Д.Г. Оценка прогноза и минимальной резидуальной болезни при В­клеточном хроническом лимфолейкозе с использованием метода многоцветной проточной цитофлуориметрии : дис. … канд. мед. наук. Москва, 2013. 113 с.

4. Кислицына М.А. и др. Особенности цитогенетической диагностики синхронно протекающих хронического лимфолейкоза и миелодиспластического синдрома: описание клинического случая // Онкогематология. 2019. Т. 14, № 3. С. 69–76.

5. Кувшинов А.Ю. и др. Хронический лимфолейкоз: прогностическое значение минимальной остаточной болезни, возможности современных методов ее выявления и коррекции (обзор литературы) // Клиническая онкогематология. 2016. Т. 9, № 2. С. 91–98.

6. Луговская С.А. и др. Новые маркеры (CD160, CD200, LAIR­1) в диагностике В­клеточных лимфопролиферативных заболеваний // Клиническая онкогематология. 2013. Т. 6, № 1. С. 45–52.

7. Миролюбова Ю.В. и др. Роль поверхностного маркера CD200 в дифференциальной диагностике злокачественных В­клеточных лимфопролиферативных заболеваний // Клиническая онкогематология. 2017. Т. 10, № 2. С. 169–175.

8. Никитин Е.А. и др. Прогностическое значение мутационного статуса генов вариабельного региона иммуноглобулинов у больных хроническим лимфолейкозом, получавших комбинированную терапию флударабином и циклофосфаном // Терапевтический архив. 2007. Т. 79, № 7. С. 66–70.

9. Никитин Е.А. Дифференцированная терапия хронического лимфолейкоза : дис. … д-ра мед. наук. Москва, 2014. 222 с.

10. Российские клинические рекомендации по диагностике и лечению лимфопролиферативных заболеваний / под ред. И.В. Поддубной, В.Г. Савченко. Москва, 2018.

11. Abrisqueta P. et al. Rituximab maintenance after firstline therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R­FCM) for chronic lymphocytic leukemia // Blood. 2013. Vol. 122, N 24. P. 3951–3959.

12. Baumann T. et al. CD49d (ITGA4) expression is a predictor of time to first treatment in patients with chronic lymphocytic leukaemia and mutated IGHV status // Br. J. Haematol. 2016. Vol. 172. P. 48–55.

13. Baskar S. et al. Unique cell surface expression of receptor tyrosine kinase ROR1 in human B­cell chronic lymphocytic leukemia // Clin. Cancer Res. 2008. Vol. 14, N 2. P. 396–404.

14. Bing Cui. Highlevel ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia // Blood. 2016. Vol. 128, N 25. P. 2931–2940.

15. Bottcher S. et al. Minimal residual disease quantification is an independent predictor of progression­free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial // J. Clin. Oncol. 2012. Vol. 30, N 9. P. 980–988.

16. Challagundla P. Differential expression of CD200 in B­cell neoplasms by flow cytometry can assist in diagnosis, subclassification, and bone marrow staging // Am. J. Clin. Pathol. 2014. Vol. 142, N 6. P. 837–844.

17. Cheminant M. et al. Minimal residual disease monitoring by 8­color flow cytometry in mantle cell lymphoma: an EU­MCL and LYSA study // Haematologica. 2016. Vol. 101, N 3. P. 336–345.

18. Chiorazzi N. Implications of new prognostic markers in chronic lymphocytic leukemia // Hematology Am. Soc. Hematol. Educ. Program. 2012. Vol. 2012, N 1. P. 76–87.

19. Chen L. et al. ZAP­70 enhances IgM signaling independent of its kinase activity in chronic lymphocytic leukemia // Blood. 2008. Vol. 111. P. 2685–2692.

20. Hsi E.D. et al. Biclonal chronic lymphocytic leukemia // Am. J. Clin. Pathol. 2000. Vol. 113. P. 798–804.

21. Crespo M. et al. ZAP­70 expression as a surrogate for immunoglobulin­variable­region mutations in chronic lymphocytic leukemia // N. Engl. J. Med. 2003. Vol. 348. P. 1764–1775.

22. Chovancova J. et al. Detection of minimal residual disease in mantle cell lymphoma – establishment of novel eight­color flow cytometry approach // Cytometry B Clin. Citom. 2015. Vol. 88, N 2. P. 92–100.

23. Dorwal P. et al. Aberrant NK cell associated marker [CD56 and CD57] expression in chronic lymphocytic leukemia // Cytometry B Clin. Citom. 2015. Vol. 88, N 5. P. 348–351.

24. van Dongen J.J. et al.; EuroFlow Consortium [EU­FP6, LSHB­CT­2006­018708]. EuroFlow antibody panels for standardized n­dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes // Leukemia. 2012. Vol. 26, N 9. P. 1908–1975.

25. D’Avola A. et al. Surface IgM expression and function are associated with clinical behavior, genetic abnormalities, and DNA methylation in CLL // Blood. 2016. Vol. 128, N 6. P. 816–826.

26. Farren T. et al. Differential and tumor­specific expression of CD160 in B­cell malignancies // Blood. 2011. Vol. 118. P. 2174–2183.

27. Hock B.D. et al. CD38 as a prognostic marker in chronic lymphocytic leukaemia at a single New Zealand centre: patient survival in comparison to age and sex matched population data // Intern. Med. J. 2010. Vol. 40. P. 842–849.

28. Hallek M. et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute Working Group 1996 Guidelines // Blood. 2008. Vol. 111. P. 5446–5456.

29. Kriston С. Low CD23 expression correlates with high CD38 expression and the presence of trisomy 12 in CLL // Hematol. Oncol. 2017. Vol. 35. P. 58–63.

30. Kienle D. et al. Gene expression factors as predictors of genetic risk and survival in chronic lymphocytic leukemia // Haematologica. 2010. Vol. 95. P. 102–109.

31. Letestu R. et al. Prognosis of Binet stage A chronic lymphocytic leukemia patients: the strength of routine parameters // Blood. 2010. Vol. 116, N 22. P. 4588–4590.

32. Lew T.E. Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months // Blood Adv. 2020. Vol. 4, N 1. P. 165–173.

33. Malavasi F. et al. CD38 and chronic lymphocytic leukemia: a decade later // Blood. 2011. Vol. 118. P. 3470–3478.

34. Monaghan S.A. et al. Pan B­cell markers are not redundant in analysis of chronic lymphocytic leukemia (CLL) // Cytometry B Clin. Citom. 2003. Vol. 56, N 1. P. 30–42.

35. Mili Jain et al. CD8 expression in B chronic lymphocytic leukemia: a case of immunophenotypic aberrancy // Cytometry B Clin. Citom. 2018. Vol. 94, N 4. P. 679–682.

36. Matos D.M. CD8 antigen expression in chronic lymphocytic leukemia: does it have any relevant meaning? // Cytometry B Clin. Citom. 2019. Vol. 96, N 2. P. 96–98. DOI: https://doi.org/10.1002/cyto.b.21759

37. Mayeur­Rousse C. et al. CD180 expression in B­cell lymphomas: a multicenter GEIL study // Cytometry B Clin. Citom. 2016. Vol. 90, N 5. P. 462–466.

38. Malavasi F. et al. Evolution and function of the ADP ribosylcyclase/CD38 gene family in physiology and pathology // Physiol. Rev. 2008. Vol. 88, N 3. P. 841–886.

39. Montillo M. et al. Chronic lymphocytic leukemia: novel prognostic factors and their relevance for risk-adapted therapeutic strategies // Haematologica. 2005. Vol. 90. P. 391–399.

40. Mariangeles A. Evaluation of CD307a expression patterns during normal B­cell maturation and in B­cell malignancies by flow cytometry // Cytometry B Clin. Citom. 2018. Vol. 94. P. 588–595.

41. Orchard J.A. et al. ZAP­70 expression and prognosis in chronic lymphocytic leukaemia // Lancet. 2004. Vol. 363. P. 105–111.

42. Ortolani C. Flow Cytometry of Hematological Malignancies. Chichester : Wiley-Blackwell, 2011. 311 p.

54. Perković S. et al. Multiparameter flow cytometry is necessary for detection, characterization and diagnostics of composite mature B­cell lymphoproliferative neoplasms // Int. J. Hematol. 2013. Vol. 98, N 5. P. 589–596. DOI: https://doi.org/10.1007/s12185­013­1432­7

43. Porwit A., Bene M.C. Multiparameter Flow Cytometry in the Diagnosis of Hematological Malignancies. Cambridge University Press, 2018. 234 p.

44. Rosenwald A. et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia // J. Exp. Med. 2001. Vol. 194. P. 1639–1647.

45. Rawstron Andy C. et al. Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: an European Research Initiative on CLL [ERIC] & European Society for Clinical Cell Analysis [ESCCA] Harmonisation project // Cytometry B Clin. Citom. 2018. Vol. 94. P. 121–128.

46. Rawstron A.C. et al. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukemia // Leukemia. 2007. Vol. 21, N 5. P. 956–964.

47. Rawstron A.C. et al. A complementary role of multiparameter flow cytometry and high­throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study // Leukemia. 2016. Vol. 30. P. 929–936.

48. Rebagay G. et al. ROR1 and ROR2 in human malignancies: potentials for targeted therapy // Front. Oncol. 2012. Vol. 2, N 34. P. 1–8.

49. Strati P. et al. Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL // Blood. 2014. Vol. 123, N 24. P. 3727–3732.

50. Sorigue M. et al. Expression of CD43 in chronic lymphoproliferative leukemias // Cytometry B Clin. Citom. 2018. Vol. 94. P. 136–142.

51. Sun Yi et al. Composite mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma // Cytometry B Clin. Citom. 2018. Vol. 94. P. 148–150.

52. Uhrmacher S. et al. Use of the receptor tyrosine kinase­like orphan receptor 1 [ROR1] as a diagnostic tool in chronic lymphocytic leukemia [CLL] // Leuk. Res. 2011. Vol. 35. P. 1360–1366.

53. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon : International Agency for Research on Cancer, 2008. 439 p.